Navigating adalimumab biosimilars: an expert opinion
The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars – (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma – for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyri...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-10-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1797383250498289664 |
|---|---|
| author | Vered Abitbol Salim Benkhalifa Caroline Habauzit Hubert Marotte |
| author_facet | Vered Abitbol Salim Benkhalifa Caroline Habauzit Hubert Marotte |
| author_sort | Vered Abitbol |
| collection | DOAJ |
| description | The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab
biosimilars – (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio,
Imraldi and Yuflyma – for the treatment of various immune and inflammatory conditions. Amjevita,
Hadlima, Hyrimoz and Yuflyma have recently become available in the USA, with others expected to
reach this market in 2023 as the US patent protection for Humira ends. Although adalimumab biosimilars
demonstrate efficacy, safety and immunogenicity similar to the originator, they may differ in product
excipient(s) and preservatives, along with their device type(s). Physicians may find it both difficult and time
consuming to navigate their way among the array of available adalimumab biosimilars when they need
to make a treatment decision. This article explores the characteristics of various adalimumab biosimilars
to help clinicians navigate the various options available across Europe and the USA. In addition to drug
selection, effective patient–physician communication is needed to nurture realistic patient expectations
and minimize potential nocebo effects when prescribing biosimilars. |
| first_indexed | 2024-03-08T21:18:13Z |
| format | Article |
| id | doaj.art-43d7e9504aba45559133591af9ccb313 |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-08T21:18:13Z |
| publishDate | 2023-10-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-43d7e9504aba45559133591af9ccb3132023-12-21T13:59:52ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132023-10-01121110.57264/cer-2023-0117Navigating adalimumab biosimilars: an expert opinionVered Abitbol0Salim Benkhalifa1Caroline Habauzit2Hubert Marotte3https://orcid.org/0000-0003-1177-9497Service de gastroenterologie, Hopital Cochin, AP-HP, Universite Paris Cite , Paris, 75014, FranceCelltrion Healthcare SAS, Issy Les Moulineaux, 92130, FranceCelltrion Healthcare SAS, Issy Les Moulineaux, 92130, FranceUniversite Jean Monnet Saint-Etienne, CHU Saint-Etienne, Service de Rhumatologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Etienne, 42023, FranceThe patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars – (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma – for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyrimoz and Yuflyma have recently become available in the USA, with others expected to reach this market in 2023 as the US patent protection for Humira ends. Although adalimumab biosimilars demonstrate efficacy, safety and immunogenicity similar to the originator, they may differ in product excipient(s) and preservatives, along with their device type(s). Physicians may find it both difficult and time consuming to navigate their way among the array of available adalimumab biosimilars when they need to make a treatment decision. This article explores the characteristics of various adalimumab biosimilars to help clinicians navigate the various options available across Europe and the USA. In addition to drug selection, effective patient–physician communication is needed to nurture realistic patient expectations and minimize potential nocebo effects when prescribing biosimilars.adalimumabbiosimilardevicedoseefficacyformulationnocebopatient expectationspatient–physician communicationsafety |
| spellingShingle | Vered Abitbol Salim Benkhalifa Caroline Habauzit Hubert Marotte Navigating adalimumab biosimilars: an expert opinion Journal of Comparative Effectiveness Research adalimumab biosimilar device dose efficacy formulation nocebo patient expectations patient–physician communication safety |
| title | Navigating adalimumab biosimilars: an expert opinion |
| title_full | Navigating adalimumab biosimilars: an expert opinion |
| title_fullStr | Navigating adalimumab biosimilars: an expert opinion |
| title_full_unstemmed | Navigating adalimumab biosimilars: an expert opinion |
| title_short | Navigating adalimumab biosimilars: an expert opinion |
| title_sort | navigating adalimumab biosimilars an expert opinion |
| topic | adalimumab biosimilar device dose efficacy formulation nocebo patient expectations patient–physician communication safety |
| work_keys_str_mv | AT veredabitbol navigatingadalimumabbiosimilarsanexpertopinion AT salimbenkhalifa navigatingadalimumabbiosimilarsanexpertopinion AT carolinehabauzit navigatingadalimumabbiosimilarsanexpertopinion AT hubertmarotte navigatingadalimumabbiosimilarsanexpertopinion |